ERBB2 and breast carcinoma: Not all drug-tolerant cells are proliferative; most HER2-amplified breast cancer cell lines that form drug-tolerant cells following HER2 inhibition do not proliferate at all for at least 8 weeks but can resume proliferation if HER2 inhibition is withdrawn [4].